The Lancet infectious diseases, 2024-06, Vol.24 (6), p.e365-e365
2024
Volltextzugriff (PDF)
Details
- Autor(en) / Beteiligte
- Titel
- Research in brief
- Ist Teil von
- The Lancet infectious diseases, 2024-06, Vol.24 (6), p.e365-e365
- Ort / Verlag
- London: Elsevier Ltd
- Erscheinungsjahr
- 2024
- Quelle
- Elsevier ScienceDirect Journals Complete
- Beschreibungen/Notizen
- A monoclonal antibody to prevent malaria in children In a phase 2 study, a subcutaneous monoclonal antibody, L9LS, was efficacious against Plasmodium falciparum infection and clinical malaria in children. The safety outcomes of mean days to intensive-care unit transfer and hospital length of stay did not differ between the groups. Researchers at Stanford University (CA, USA) undertook single-cell RNA sequencing to investigate cellular tropism and individual cell effects of SARS-CoV-2 infection in healthy human lung tissue samples.
- Sprache
- Englisch
- Identifikatoren
- ISSN: 1473-3099eISSN: 1474-4457DOI: 10.1016/S1473-3099(24)00305-0Titel-ID: cdi_proquest_journals_3058531980
- Format
- –
- Schlagworte
- Antibiotics, Bacteria, COVID-19 vaccines, Gene sequencing, Gram-negative bacteria, Malaria, Monoclonal antibodies, mRNA vaccines, Multidrug resistant organisms, Penicillin, Plasmodium falciparum, Pneumonia, Researchers, Severe acute respiratory syndrome coronavirus 2, Tropism, Urinary tract infections, Vector-borne diseases